Special Issue "DNA Vaccines"

Quicklinks

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (15 May 2013)

Special Issue Editors

Guest Editor
Prof. Dr. Margaret A. Liu
1 ProTherImmune, 3656 Happy Valley Road Lafayette, CA 94549, USA
2 Karolinska Institute, Stockholm SE-17177, Sweden
3. Adjunct Professor, Department of Microbiology and Immunology, University of California, San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143 USA
Website: http://ki.se/ki/jsp/polopoly.jsp?d=23327&a=36147&l=en
E-Mail: liu@protherimmune.com
Phone: +1 925 299 2959
Fax: +1 925 299 2959
Interests: vaccine technologies; DNA vaccines; cellular immune responses; HIV Vvccines; global health

Co-Guest Editor
Prof. Dr. Britta Wahren
Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet Center for HIV research, Nobel´s Road 16, 171 77 Stockholm, Sweden
Website: http://ki.se/ki/jsp/polopoly.jsp?d=23486&a=34947&l=en
E-Mail: Britta.Wahren@ki.se
Interests: infectious diseases; virology; tumor biology; HIV vaccines; genetic vaccines

Special Issue Information

Dear Colleagues,

During the last few years, there has been immense progress in the field of gene-based vaccines. This has been a result of new and better vectors, improved expression constructs, different types of delivery methods and devices, and it may be said, selection of optimal diseases/antigens and vaccinees. Several products have been licensed for veterinary applications, including infectious diseases and cancer. New human clinical trials have been initiated, and a number of phase 1-2 trials concluded. The present issue on “Research progress for gene-based vaccines” will bring together primary data and up-to-date summaries of break-throughs in using DNA plasmids for vaccines and immunotherapies. It will also show the possibilities of gene therapy, for which there is one licensed veterinary product and a different human one. To exemplify the progress, the situation for several severe infectious diseases and tumors will be depicted together with future views for further translation into the clinic.

It is 20 years since the first data on DNA vaccines were publicly presented at Cold Spring Harbor, 1992. Clinical trials of DNA vaccines are in progress for many diseases including HIV, HCV, malaria, influenza, tuberculosis and tumors (colo-rectal, prostate, melanoma). These include plasmid constructs used as a prime for boosting with other types of vaccines.

Prof. Dr. Margaret A. Liu
Prof. Dr. Britta Wahren
Guest Editors

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. For the first couple of issues the Article Processing Charge (APC) will be waived for well-prepared manuscripts. English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

Keywords

  • DNA vaccine
  • RNA vaccine
  • infectious diseases
  • autoimmune diseases
  • allergy
  • immune mechanisms
  • antibodies
  • T cells
  • innate immunity
  • delivery technology
  • prime-boost
  • adjuvants
  • electroporation
  • prophylaxis

Published Papers (16 papers)

by , , , , , , , , , , , , , , , , , ,  and
Vaccines 2014, 2(3), 563-580; doi:10.3390/vaccines2030563
Received: 27 February 2014; in revised form: 26 June 2014 / Accepted: 27 June 2014 / Published: 17 July 2014
Show/Hide Abstract | PDF Full-text (1114 KB) | HTML Full-text | XML Full-text

by , , ,  and
Vaccines 2014, 2(2), 354-379; doi:10.3390/vaccines2020354
Received: 21 February 2014; in revised form: 11 April 2014 / Accepted: 18 April 2014 / Published: 14 May 2014
Show/Hide Abstract | PDF Full-text (821 KB) | HTML Full-text | XML Full-text
abstract graphic

by , , , , , , , , , ,  and
Vaccines 2014, 2(2), 196-215; doi:10.3390/vaccines2020196
Received: 27 November 2013; in revised form: 31 January 2014 / Accepted: 28 February 2014 / Published: 25 March 2014
Show/Hide Abstract | PDF Full-text (1452 KB) | HTML Full-text | XML Full-text

by , , ,  and
Vaccines 2014, 2(1), 181-195; doi:10.3390/vaccines2010181
Received: 23 January 2014; in revised form: 12 February 2014 / Accepted: 19 February 2014 / Published: 5 March 2014
Show/Hide Abstract | Cited by 1 | PDF Full-text (810 KB) | HTML Full-text | XML Full-text

by  and
Vaccines 2014, 2(1), 160-178; doi:10.3390/vaccines2010160
Received: 6 January 2014; in revised form: 31 January 2014 / Accepted: 6 February 2014 / Published: 28 February 2014
Show/Hide Abstract | PDF Full-text (827 KB) | HTML Full-text | XML Full-text

by ,  and
Vaccines 2014, 2(1), 89-106; doi:10.3390/vaccines2010089
Received: 15 October 2013; in revised form: 22 November 2013 / Accepted: 26 November 2013 / Published: 13 January 2014
Show/Hide Abstract | PDF Full-text (381 KB) | HTML Full-text | XML Full-text

by ,  and
Vaccines 2014, 2(1), 36-48; doi:10.3390/vaccines2010036
Received: 11 October 2013; in revised form: 26 November 2013 / Accepted: 5 December 2013 / Published: 27 December 2013
Show/Hide Abstract | PDF Full-text (653 KB) | HTML Full-text | XML Full-text

by , , , , , , ,  and
Vaccines 2013, 1(4), 463-480; doi:10.3390/vaccines1040463
Received: 30 July 2013; in revised form: 10 September 2013 / Accepted: 9 October 2013 / Published: 18 October 2013
Show/Hide Abstract | PDF Full-text (459 KB) | HTML Full-text | XML Full-text

by , , , , , , , , ,  and
Vaccines 2013, 1(4), 415-443; doi:10.3390/vaccines1040415
Received: 18 July 2013; in revised form: 27 August 2013 / Accepted: 30 August 2013 / Published: 25 September 2013
Show/Hide Abstract | PDF Full-text (940 KB) | HTML Full-text | XML Full-text

by , , ,  and
Vaccines 2013, 1(4), 398-414; doi:10.3390/vaccines1040398
Received: 10 July 2013; in revised form: 23 August 2013 / Accepted: 28 August 2013 / Published: 25 September 2013
Show/Hide Abstract | PDF Full-text (550 KB) | HTML Full-text | XML Full-text

by , , , , , ,  and
Vaccines 2013, 1(3), 384-397; doi:10.3390/vaccines1030384
Received: 16 July 2013; in revised form: 13 August 2013 / Accepted: 21 August 2013 / Published: 28 August 2013
Show/Hide Abstract | Cited by 1 | PDF Full-text (837 KB) | HTML Full-text | XML Full-text

by , , , , , , , ,  and
Vaccines 2013, 1(3), 367-383; doi:10.3390/vaccines1030367
Received: 26 June 2013; in revised form: 12 August 2013 / Accepted: 14 August 2013 / Published: 22 August 2013
Show/Hide Abstract | Cited by 2 | PDF Full-text (1824 KB) | HTML Full-text | XML Full-text

by , , , , , , , , , , , , , , , ,  and
Vaccines 2013, 1(3), 305-327; doi:10.3390/vaccines1030305
Received: 16 May 2013; in revised form: 5 July 2013 / Accepted: 10 July 2013 / Published: 19 July 2013
Show/Hide Abstract | PDF Full-text (724 KB) | HTML Full-text | XML Full-text | Supplementary Files

by , , , , ,  and
Vaccines 2013, 1(3), 278-292; doi:10.3390/vaccines1030278
Received: 13 June 2013; in revised form: 6 July 2013 / Accepted: 9 July 2013 / Published: 18 July 2013
Show/Hide Abstract | Cited by 3 | PDF Full-text (685 KB) | HTML Full-text | XML Full-text

by , , , , , , , , ,  and
Vaccines 2013, 1(3), 262-277; doi:10.3390/vaccines1030262
Received: 31 May 2013; in revised form: 8 July 2013 / Accepted: 10 July 2013 / Published: 18 July 2013
Show/Hide Abstract | PDF Full-text (512 KB) | HTML Full-text | XML Full-text

by
Vaccines 2013, 1(3), 225-249; doi:10.3390/vaccines1030225
Received: 14 May 2013; in revised form: 12 June 2013 / Accepted: 18 June 2013 / Published: 25 June 2013
Show/Hide Abstract | Cited by 1 | PDF Full-text (653 KB) | HTML Full-text | XML Full-text
abstract graphic

Last update: 16 January 2013

Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert